Thursday, October 06, 2022 4:55:12 PM
see replied to post for previous day
10/06/22 16:00:04 11.03 10.96 11.10 12,500
10/06/22 16:00:04 11.03 10.96 11.10 1,300
10/06/22 16:00:04 11.03 10.96 11.10 1,100
10/06/22 16:00:01 11.03 11.01 11.10 1,100
10/06/22 16:00:01 11.03 11.01 11.10 1,700
10/06/22 16:00:00 11.03 11.01 11.02 147,300
10/06/22 15:58:59 11.0201 11.02 11.04 1,000
10/06/22 15:58:36 11.0326 11.03 11.04 2,500
10/06/22 15:56:33 11.07 11.06 11.07 1,676
10/06/22 15:55:57 11.0608 11.05 11.06 1,700
10/06/22 15:55:22 11.0595 11.05 11.07 2,000
10/06/22 15:54:50 11.07 11.06 11.07 1,700
10/06/22 15:54:50 11.06 11.06 11.07 1,304
10/06/22 15:54:50 11.06 11.06 11.07 1,062
10/06/22 15:54:40 11.05 11.05 11.06 1,237
10/06/22 15:51:47 11.11 11.11 11.12 2,700
10/06/22 15:51:10 11.1199 11.11 11.12 2,300
10/06/22 15:51:04 11.12 11.11 11.12 1,000
10/06/22 15:50:36 11.1301 11.13 11.14 1,500
10/06/22 15:50:00 11.115 11.12 11.14 3,548
10/06/22 15:47:38 11.135 11.13 11.14 1,000
10/06/22 15:41:07 11.0953 11.09 11.10 1,100
10/06/22 15:26:48 11.12 11.12 11.13 2,000
10/06/22 15:24:15 11.11 11.09 11.11 5,000
10/06/22 15:21:52 11.125 11.11 11.14 1,450
10/06/22 15:21:52 11.15 11.14 11.15 2,200
10/06/22 15:21:52 11.15 11.14 11.15 1,100
10/06/22 15:21:52 11.15 11.14 11.15 1,500
10/06/22 15:21:52 11.15 11.14 11.15 1,200
10/06/22 15:21:35 11.15 11.14 11.15 1,000
10/06/22 15:21:35 11.1418 11.14 11.15 1,000
10/06/22 15:18:36 11.11 11.09 11.11 1,000
10/06/22 15:13:21 11.11 11.09 11.10 3,900
10/06/22 15:03:41 11.00 11.00 11.03 2,000
10/06/22 14:57:29 10.9848 10.97 10.99 4,500
10/06/22 14:54:10 10.93 10.93 10.94 1,400
10/06/22 14:18:52 11.0101 11.01 11.03 1,000
10/06/22 14:13:43 11.03 11.00 11.03 1,000
10/06/22 14:04:13 10.9996 10.99 11.00 1,000
10/06/22 14:02:49 10.9888 10.98 10.99 2,000
10/06/22 13:57:02 11.00 10.97 11.00 1,000
10/06/22 13:20:58 10.98 10.97 10.98 1,000
10/06/22 13:19:25 10.955 10.95 10.96 1,000
10/06/22 12:27:39 10.84 10.82 10.84 1,500
10/06/22 12:24:19 10.84 10.84 10.85 1,400
10/06/22 11:51:13 10.8401 10.84 10.86 3,000
10/06/22 11:49:29 10.8303 10.83 10.86 1,400
10/06/22 10:59:10 10.79 10.79 10.80 3,509
10/06/22 10:50:32 10.8196 10.80 10.82 1,000
10/06/22 10:43:16 10.7489 10.73 10.75 1,700
10/06/22 10:34:47 10.7089 10.69 10.71 1,000
10/06/22 10:29:38 10.67 10.66 10.67 1,400
10/06/22 10:28:55 10.68 10.68 10.70 2,700
10/06/22 10:22:34 10.7001 10.70 10.73 5,100
10/06/22 10:19:19 10.7199 10.68 10.72 4,000
10/06/22 10:18:31 10.74 10.74 10.77 1,100
10/06/22 10:00:18 10.80 10.78 10.80 1,000
10/06/22 09:59:41 10.795 10.78 10.81 1,000
10/06/22 09:46:51 10.87 10.85 10.89 2,000
10/06/22 09:42:51 10.9397 10.91 10.96 1,400
10/06/22 09:36:54 10.95 10.95 10.98 11,000
10/06/22 09:36:54 10.95 10.95 10.98 2,900
10/06/22 09:36:52 10.95 10.95 10.98 1,000
10/06/22 09:36:05 10.8715 10.87 10.94 1,000
10/06/22 09:35:38 10.90 10.88 10.90 2,100
10/06/22 09:33:02 10.78 10.67 10.75 1,100
10/06/22 09:33:02 10.78 10.67 10.75 2,000
10/06/22 09:32:42 10.7599 10.67 10.76 5,000
10/06/22 09:30:18 10.6501 10.65 10.79 5,000
10/06/22 09:30:01 10.71 10.70 10.89 4,500
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
